CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $21
A Quick Look at Today's Ratings for Y-mAbs Therapeutics(YMAB.US), With a Forecast Between $21 to $26
Y-mAbs Therapeutics Analyst Ratings
Truist Financial Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)
Buy Rating on Y-mAbs Therapeutics: Robust Sales Growth and Strong Pipeline Prospects
JonesTrading Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)
Recommendation to Sell on Y-Mabs Therapeutics Amid Reduced Sales Forecast and Concerns Over Profitability
Y-mAbs Therapeutics Analyst Ratings
Y-mAbs Therapeutics Analyst Ratings
Y-mAbs Therapeutics Analyst Ratings
Bank of America Securities Sticks to Its Hold Rating for Y-Mabs Therapeutics (YMAB)
Maintaining Buy Rating on Y-Mabs Therapeutics: A Financial and Clinical Catalyst Outlook
Buy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy Platform
Y-mAbs Therapeutics Analyst Ratings
Y-mAbs Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Eli Lilly & Co (LLY) and 4D Molecular Therapeutics (FDMT)
Y-mAbs Therapeutics Analyst Ratings
Buy Rating Affirmed for Y-Mabs Therapeutics on SADA Technology's Promising Radiotherapy Advancements